Your browser is no longer supported. Please, upgrade your browser.
XNCR Xencor, Inc. monthly Stock Chart
XNCR [NASD]
Xencor, Inc.
Index- P/E- EPS (ttm)-1.08 Insider Own0.60% Shs Outstand56.95M Perf Week4.76%
Market Cap1.82B Forward P/E- EPS next Y-1.28 Insider Trans-71.81% Shs Float55.84M Perf Month9.71%
Income-61.20M PEG- EPS next Q-0.48 Inst Own93.20% Short Float5.44% Perf Quarter13.12%
Sales77.10M P/S23.57 EPS this Y135.20% Inst Trans-1.94% Short Ratio5.46 Perf Half Y-6.02%
Book/sh10.41 P/B3.15 EPS next Y14.10% ROA-9.00% Target Price44.17 Perf Year-25.44%
Cash/sh10.34 P/C3.17 EPS next 5Y- ROE-10.20% 52W Range19.35 - 46.33 Perf YTD-4.74%
Dividend- P/FCF21.74 EPS past 5Y23.50% ROI2.30% 52W High-29.29% Beta1.05
Dividend %- Quick Ratio8.90 Sales past 5Y75.10% Gross Margin- 52W Low69.30% ATR1.65
Employees166 Current Ratio8.90 Sales Q/Q-71.00% Oper. Margin-94.80% RSI (14)56.42 Volatility4.73% 5.78%
OptionableYes Debt/Eq0.00 EPS Q/Q-110.30% Profit Margin-79.40% Rel Volume0.73 Prev Close32.82
ShortableNo LT Debt/Eq0.00 Earnings- Payout- Avg Volume556.64K Price32.76
Recom2.00 SMA204.98% SMA505.47% SMA200-2.26% Volume402,743 Change-0.18%
Mar-04-20Initiated Barclays Underweight $28
Feb-25-20Upgrade Guggenheim Neutral → Buy $43
Jan-30-20Initiated RBC Capital Mkts Outperform $44
Nov-20-19Resumed Guggenheim Neutral
Aug-07-19Downgrade Raymond James Outperform → Mkt Perform
Aug-07-19Downgrade Guggenheim Buy → Neutral
Jun-13-19Initiated Mizuho Buy
Apr-12-19Initiated Guggenheim Buy
Mar-27-19Initiated Berenberg Buy $45
Mar-15-19Initiated Raymond James Outperform
Sep-10-18Resumed BTIG Research Buy $56
Mar-28-18Resumed Leerink Partners Outperform $36
Mar-02-17Reiterated Wedbush Outperform $27 → $33
Mar-02-17Initiated Instinet Neutral $21
Oct-04-16Initiated Piper Jaffray Overweight
Dec-22-15Initiated Canaccord Genuity Buy $20
Aug-05-15Reiterated MLV & Co Buy $22 → $29
Feb-12-15Reiterated Oppenheimer Outperform $22 → $28
Jan-28-15Reiterated MLV & Co Buy $18 → $22
Jul-11-14Initiated Oppenheimer Outperform $22
Jun-30-20 11:35PM  
Jun-22-20 09:06AM  
Jun-08-20 01:48PM  
May-26-20 04:01PM  
May-15-20 12:01AM  
May-13-20 05:00PM  
09:01AM  
May-11-20 01:35PM  
May-08-20 09:30PM  
May-07-20 04:01PM  
Apr-30-20 04:01PM  
Apr-13-20 03:49PM  
Apr-07-20 02:10PM  
Mar-26-20 08:23AM  
Mar-25-20 04:01PM  
Mar-02-20 02:55PM  
Feb-28-20 07:43AM  
Feb-26-20 11:59AM  
Feb-24-20 05:45PM  
04:01PM  
Feb-18-20 08:01AM  
Feb-17-20 12:30PM  
Feb-06-20 04:01PM  
Feb-05-20 10:28AM  
08:01AM  
Jan-09-20 05:10PM  
Jan-08-20 12:08PM  
08:01AM  
Dec-30-19 10:13AM  
Dec-20-19 08:01AM  
Dec-18-19 08:01AM  
Dec-14-19 08:05PM  
Dec-09-19 10:00AM  
Nov-19-19 12:58PM  
10:33AM  
Nov-18-19 11:48PM  
Nov-13-19 04:01PM  
Nov-06-19 09:00AM  
Nov-05-19 06:05PM  
04:01PM  
Oct-29-19 04:01PM  
Oct-28-19 10:31AM  
Oct-21-19 12:55PM  
Oct-10-19 03:34PM  
Sep-26-19 04:01PM  
Sep-10-19 04:01PM  
Aug-23-19 10:00AM  
Aug-22-19 09:15PM  
Aug-21-19 06:53AM  
Aug-08-19 11:13AM  
Aug-06-19 06:05PM  
04:01PM  
Aug-01-19 04:01PM  
Jul-30-19 04:01PM  
Jul-12-19 06:16PM  
Jul-09-19 12:52PM  
Jul-02-19 08:58AM  
Jun-27-19 08:01AM  
Jun-26-19 10:12AM  
Jun-24-19 06:00PM  
01:38PM  
Jun-08-19 09:14AM  
Jun-03-19 08:01AM  
May-23-19 08:01AM  
May-10-19 09:23AM  
May-09-19 04:43PM  
04:00PM  
May-08-19 04:01PM  
May-06-19 08:01AM  
May-02-19 04:01PM  
May-01-19 01:22PM  
Apr-30-19 08:01AM  
Apr-29-19 09:55PM  
Apr-02-19 08:01AM  
Apr-01-19 04:05PM  
12:55PM  
Mar-08-19 08:01AM  
Mar-06-19 07:00AM  
Mar-01-19 12:30PM  
06:18AM  
Feb-28-19 09:15AM  
Feb-26-19 09:48PM  
09:11AM  
Feb-25-19 09:05PM  
04:24PM  
02:30PM  
09:12AM  
Feb-23-19 09:15AM  
Feb-20-19 06:55AM  
Feb-19-19 09:01AM  
Feb-07-19 09:01AM  
Feb-05-19 08:01AM  
Jan-28-19 07:35AM  
Jan-21-19 06:12AM  
Jan-07-19 08:01AM  
Dec-06-18 10:45AM  
Dec-04-18 07:35AM  
Dec-03-18 05:45PM  
Nov-20-18 09:01AM  
Nov-08-18 09:01AM  
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat cancer and autoimmune diseases. The company's product candidates include XmAb5871, an immune inhibitor, which has been completed Phase II clinical trial for the treatment of autoimmune diseases; AIMab7195, which is in development and commercialization stage. Its product candidates also comprise XmAb14045, a bispecific antibody which is in Phase I clinical trial for the treatment of acute myeloid leukemia; plamotamab (XmAb13676) that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers Tafasitamab, an antibody drug candidate for the treatment of patients with relapsed/refractory diffuse; AMG424, a bispecific antibody that targets CD38 and CD3, which is in Phase I clinical trial for the treatment of various myeloma; and AMG509, a bispecific antibody that is in preclinical development stage to treat prostate cancer. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, and XmAb23104 which are in preclinical Phase. Additionally, it offers XmAb24306, initial cytokine candidate which is in Phase I clinical trial. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc.; MorphoSys Ag; Amgen Inc.; and Catalent Pharma Solutions LLC. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kuch John JSr. Vice President & CFOJun 12Option Exercise11.0510,000110,50090,602Jun 16 08:45 PM
STAFFORD JOHN S III10% OwnerApr 06Sale27.43644,77117,685,509606,005Apr 08 04:26 PM
Ronin Capital, LLC10% OwnerMar 20Sale29.8950,7701,517,6425,012,430Mar 23 05:37 PM
Ronin Capital, LLC10% OwnerMar 19Sale28.2326,800756,5935,063,200Mar 23 05:37 PM
STAFFORD JOHN S III10% OwnerJan 08Sale36.6860,8762,232,9321,250,776Jan 08 05:28 PM
STAFFORD JOHN S III10% OwnerJan 07Sale35.956,047217,3901,311,652Jan 08 05:28 PM
STAFFORD JOHN S III10% OwnerJan 06Sale35.8158,8622,107,9071,317,699Jan 08 05:28 PM
STAFFORD JOHN S III10% OwnerDec 26Sale40.044,119164,9251,376,561Dec 26 05:07 PM
STAFFORD JOHN S III10% OwnerDec 24Sale39.7143,7201,736,1211,380,680Dec 26 05:07 PM
STAFFORD JOHN S III10% OwnerDec 23Sale39.5191,6773,622,3421,424,400Dec 26 05:07 PM
STAFFORD JOHN S III10% OwnerDec 20Sale39.3973,4232,892,1321,516,077Dec 26 05:07 PM
STAFFORD JOHN S III10% OwnerDec 11Sale38.6837,9511,467,9451,589,500Dec 11 06:48 PM
STAFFORD JOHN S III10% OwnerDec 10Sale40.13252,22510,121,7891,627,451Dec 11 06:48 PM
STAFFORD JOHN S III10% OwnerDec 09Sale41.64120,3245,009,7501,879,676Dec 11 06:48 PM
Desjarlais John RSr. V.P., Research & CSOSep 06Option Exercise4.2527,522116,96983,868Sep 10 06:12 PM
Kuch John JSr. Vice President & CFOAug 21Option Exercise11.0520,000221,000113,629Aug 22 07:59 PM
Kuch John JSr. Vice President & CFOAug 21Sale41.2740,0001,650,72473,629Aug 22 07:59 PM
Desjarlais John RSr. V.P., Research & CSOAug 19Sale40.6935,0001,424,15056,346Aug 21 04:21 PM